IL1B and COVID-19: Additionally, a large RCT done in 342 COVID-19 patients with signs of cytokine release syndrome found that drugs targeting IL-1 (anakinra) or IL-6 (tocilizumab or siltuximab) did not shorten the time to clinical improvement [93].